Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-25T11:05:24.920Z Has data issue: false hasContentIssue false
  • English
  • Français

Cyproheptadine Treatment in Neuroleptic-Induced Akathisia

Published online by Cambridge University Press:  02 January 2018

David Weiss ,
Dov Aizenberg ,
Haggai Hermesh ,
Zvi Zemishlany ,
Hanan Munitz ,
Margaret Radwan  and
Abraham Weizman
David Weiss
Affiliation:
Gehah Psychiatric Hospital, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University
Dov Aizenberg*
Affiliation:
Gehah Psychiatric Hospital, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University
Haggai Hermesh
Affiliation:
Gehah Psychiatric Hospital, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University
Zvi Zemishlany
Affiliation:
Gehah Psychiatric Hospital, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University
Hanan Munitz
Affiliation:
Gehah Psychiatric Hospital, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University
Margaret Radwan
Affiliation:
Gehah Psychiatric Hospital, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University
Abraham Weizman
Affiliation:
Gehah Psychiatric Hospital and Felsenstein Medical Research Center, Petah Tiqva and Sackler Faculty of Medicine, Tel Aviv University
*
Dr Dov Aizenberg, Gehah Psychiatric Hospital, Beilinson Medical Center, PO Box 102, Petah Tiqva 49 100, Israel
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Cyproheptadine, an antiserotonergic agent, was used to treat neuroleptic-induced akathisia.

Method

In an open clinical trial 17 neuroleptic-treated patients with akathisia were administered cyproheptadine (16 mg/day) over 4 days. Assessment of akathisia, psychosis and depression were monitored by BAS, BPRS and HAM-D.

Results

All subjects showed improvement in the severity of akathisia, which in the majority (15/17) was of a marked degree. There was no aggravation of psychosis or depression. Symptoms of akathisia returned when cyproheptadine was discontinued.

Conclusions

Cyproheptadine may be useful in neuroleptic-induced akathisia.

Type
Papers
Information
The British Journal of Psychiatry , Volume 167 , Issue 4 , October 1995 , pp. 483 - 486
Copyright
Copyright © 1995 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Barnes, T. R. E. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676.Google Scholar
Barnes, T. R. E., Halstead, S. M. & Little, P. W. A. (1992) Relationship between iron status and chronic akathisia in an in-patient population with chronic schizophrenia. British Journal of Psychiatry, 161, 791–796.Google Scholar
Garrison, J. C. (1990) Histamine, bradykinin, 5-HT and their antagonists. In Goodman and Gilman's The Pharmacological Basis of Therapeutics (eds Gilman, A. G., Rall, T. W., Nies, A. S., et al), pp. 575–599. New York: Pergamon Press.Google Scholar
Guy, W. (1976) ECDEU Assessment Manual for Psychopharmacology (rev. edn). Washington, DC: US Department of Health, Education and Welfare.Google Scholar
Hamilton, M. (1960) A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry, 23, 56–62.CrossRefGoogle ScholarPubMed
Lipinski, J. F. Jr, Mallya, G., Zimmerman, P., et al (1989) Fluoxetine induced akathisia: clinical and theoretical implications. Journal of Clinical Psychiatry, 50, 339–342.Google Scholar
Marsden, C. D. & Jenner, P. (1980) The pathophysiology of extrapyramidal side effects of neuroleptic drugs. Psychological Medicine, 10, 55–72.CrossRefGoogle ScholarPubMed
Miller, C. H., Fleishacker, W. W., Ehrmann, H., et al (1990) Treatment of neuroleptic-induced akathisia with the 5HT2 antagonist ritanserin. Psychopharmacology Bulletin, 26, 373–376.Google Scholar
Overall, J. E. & Gorham, D. R. (1962) The brief psychiatric rating scale. Psychology Report, 10, 799–812.Google Scholar
Power, A. C. & Cowen, P. J. (1992) Fluoxetine and suicidal behavior: some clinical and theoretical aspects of a controversy. British Journal of Psychiatry, 161, 735–741.Google Scholar
Sadchev, P. & Loneragan, M. A. (1991) The present status of akathisia. Journal of Nervous and Mental Diseases, 179, 381–391.Google Scholar
Silver, H., Blackler, M., Weller, M. P. I., et al (1991) The treatment of chronic schizophrenia with cyproheptadine: A double blind placebo-controlled study. Biological Psychiatry, 30, 523–535.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.